Emerging microfluidics-enabled platforms for osteoarthritis management: From benchtop to bedside

Zou，Zhou1,2; Luo，Xiaohe2; Chen，Zhengkun2,3; Zhang，Yu Shrike4; Wen，Chunyi2,5

2022

10.7150/thno.62685

Theranostics   影响因子和分区

1838-7640

1838-7640

Osteoarthritis (OA) is a prevalent debilitating age-related joint degenerative disease. It is a leading cause of pain and functional disability in older adults. Unfortunately, there is no cure for OA once the damage is established. Therefore, it promotes an urgent need for early detection and intervention of OA. Theranostics, combining therapy and diagnosis, emerges as a promising approach for OA management. However, OA theranostics is still in its infancy. Three fundamental needs have to be firstly fulfilled: i) a reliable OA model for disease pathogenesis investigation and drug screening, ii) an effective and precise diagnostic platform, and iii) an advanced fabrication approach for drug delivery and therapy. Meanwhile, microfluidics emerges as a versatile technology to address each of the needs and eventually boost the development of OA theranostics. Therefore, this review focuses on the applications of microfluidics, from benchtop to bedside, for OA modelling and drug screening, early diagnosis, and clinical therapy. We first introduce the basic pathophysiology of OA and point out the major unfilled research gaps in current OA management including lack of disease modelling and drug screening platforms, early diagnostic modalities and disease-modifying drugs and delivery approaches. Accordingly, we then summarize the state-of-the-art microfluidics technology for OA management from in vitro modelling and diagnosis to therapy. Given the existing promising results, we further discuss the future development of microfluidic platforms towards clinical translation at the crossroad of engineering and biomedicine.

Biosensor Intra-articular injection Microfluidics Organ-on-a-chip Osteoarthritis

SCI

英语

第一

Health and Medical Research Fund Scheme["01150087",16172691] ; Research Grants Council of Hong Kong ECS[PolyU 251008/18M] ; GRF["PolyU 151061/20M","PolyU15100821M"] ; NFSC/RGC schemes[N_PolyU 520/20] ; ITF MHKJFS[MHP/011/20]

Research & Experimental Medicine

Medicine, Research & Experimental

WOS:000740076300024

IVYSPRING INT PUBL

2-s2.0-85121905188

Scopus

1.Department of Biomedical Engineering,Faculty of Engineering,Southern University of Science and Technology,Shenzhen,Guangdong,China
2.Department of Biomedical Engineering,Faculty of Engineering,The Hong Kong Polytechnic University,Hong Kong
3.Department of Chemistry,University of Toronto,Toronto,M5S 3H6,Canada
4.Division of Engineering in Medicine,Department of Medicine,Brigham and Women's Hospital,Harvard Medical School,Cambridge,02139,United States
5.Research Institute of Smart Ageing,The Hong Kong Polytechnic University,Hong Kong

Zou，Zhou,Luo，Xiaohe,Chen，Zhengkun,et al. Emerging microfluidics-enabled platforms for osteoarthritis management: From benchtop to bedside[J]. Theranostics,2022,12(2):891-909.

Zou，Zhou,Luo，Xiaohe,Chen，Zhengkun,Zhang，Yu Shrike,&Wen，Chunyi.(2022).Emerging microfluidics-enabled platforms for osteoarthritis management: From benchtop to bedside.Theranostics,12(2),891-909.

Zou，Zhou,et al."Emerging microfluidics-enabled platforms for osteoarthritis management: From benchtop to bedside".Theranostics 12.2(2022):891-909.